Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC) Study Results and Conclusions
Explore the STRIIVING study on switching to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC) in HIV-1-infected individuals with stable viral suppression. The study compares the efficacy of switching to DTG-ABC-3TC versus continuing current antiretroviral therapy (ART), demonstrating non-inferiority in viral suppression. Consider ABC/DTG/3TC as a viable option for regimen switches in HIV-1-infected adults. Sponsored by the National HIV Curriculum and supported by HRSA, this research sheds light on treatment strategies for HIV management.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Switch to Dolutegravir-Abacavir-Lamivudine STRIIVING Study
Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC) STRIIVING: Design Background - Open-label, randomized study, phase 3 trial comparing switch to dolutegravir-abacavir-lamivudine (DTG-ABC- 3TC) versus continuation of baseline ART Week 0 Week 24 Week 48 Early Switch Group DTG-ABC-3TC (n = 275) Inclusion Criteria (n = 553) - HIV RNA <50 copies/mL on ART - Stable on current ART for 6 months - No prior virologic failure - HLA-B*5701 negative Late Switch Group Baseline ART* (n = 278) Late Switch Group DTG-ABC-3TC (n = 244) Treatment Arms - Switch to DTG-ABC-3TC - Continuation of baseline ART* x 24 weeks, then switch to DTG-ABC-3TC *Baseline antiretroviral therapy (ART): 2 NRTIs + anchor drug (INSTI, NNRTI, or boosted PI) Source: Trottier B, et al. Antivir Ther. 2017;22:295-305.
Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC) STRIIVING: Results Week 24 and 48 Virologic Response Early Switch Group Late Switch Group 100 HIV RNA <50 copies/mL (%) 92 88 80 85 83 60 40 20 234/275 245/278 228/275 224/244 0 Week 24 Week 48 Source: Trottier B, et al. Antivir Ther. 2017;22:295-305.
Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC) STRIIVING: Conclusions Conclusions: Data demonstrating non-inferiority of switching to ABC/DTG/3TC versus continuing current ART support ABC/DTG/3TC as an option when considering switch regimens in HIV-1-infected adults with stable viral suppression. Source: Trottier B, et al. Antivir Ther. 2017;22:295-305.
Acknowledgments The National HIV Curriculum is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington s Infectious Diseases Education and Assessment (IDEA) Program.
